Ming Yin

Summary

Affiliation: Laboratory Corporation of America
Country: USA

Publications

  1. pmc Diagnostic utility of p501s (prostein) in comparison to prostate specific antigen (PSA) for the detection of metastatic prostatic adenocarcinoma
    Ming Yin
    Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
    Diagn Pathol 2:41. 2007
  2. doi p16ink4 immunoreactivity is a reliable marker for urothelial carcinoma in situ
    Ming Yin
    Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA 15232, USA
    Hum Pathol 39:527-35. 2008
  3. pmc Amylase α-1A (AMY1A): a novel immunohistochemical marker to differentiate chromophobe renal cell carcinoma from benign oncocytoma
    Sarika Jain
    Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA Department of Pathology, East Carolina University, Greenville, NC
    Am J Surg Pathol 37:1824-30. 2013
  4. pmc Angiomyolipoma with epithelial cysts (AMLEC): a rare but distinct variant of angiomyolipoma
    Henry B Armah
    Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
    Diagn Pathol 2:11. 2007
  5. doi Prevalence of incidental prostate cancer in the general population: a study of healthy organ donors
    Ming Yin
    Department of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
    J Urol 179:892-5; discussion 895. 2008

Collaborators

Detail Information

Publications5

  1. pmc Diagnostic utility of p501s (prostein) in comparison to prostate specific antigen (PSA) for the detection of metastatic prostatic adenocarcinoma
    Ming Yin
    Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
    Diagn Pathol 2:41. 2007
    ..It has not been detected in any other normal or malignant tissues. The purpose of this study was to evaluate the expression of P501s in metastatic prostatic adenocarcinoma and compare its expression with PSA...
  2. doi p16ink4 immunoreactivity is a reliable marker for urothelial carcinoma in situ
    Ming Yin
    Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA 15232, USA
    Hum Pathol 39:527-35. 2008
    ..Alterations of 9p21/chromosome 9 detected by fluorescence in situ hybridization can also be used for diagnostic confirmation and prognostic prediction...
  3. pmc Amylase α-1A (AMY1A): a novel immunohistochemical marker to differentiate chromophobe renal cell carcinoma from benign oncocytoma
    Sarika Jain
    Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA Department of Pathology, East Carolina University, Greenville, NC
    Am J Surg Pathol 37:1824-30. 2013
    ..95-1.00) and 90.74% (95% confidence interval, 0.80-0.97), respectively. These data show that the novel marker AMY1A can be of great diagnostic utility when trying to differentiate ChRCC (classic and eosinophilic variant) and oncocytoma. ..
  4. pmc Angiomyolipoma with epithelial cysts (AMLEC): a rare but distinct variant of angiomyolipoma
    Henry B Armah
    Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
    Diagn Pathol 2:11. 2007
    ..The cyst lining was positive for pancytokeratin, but negative for HMB-45, Melan-A, ER, PR, and CD10. The patient is alive with no evidence of disease, 12 months postoperatively, and yearly follow-up CT scans are planned...
  5. doi Prevalence of incidental prostate cancer in the general population: a study of healthy organ donors
    Ming Yin
    Department of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
    J Urol 179:892-5; discussion 895. 2008
    ..We analyzed our data set of incidental prostate cancer, derived from a project accruing prostate tissues for research from normal organ donors, who are a predominantly white population...